Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Jahr

2013

Autoren

Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E.

Verlag

Lancet Neurol. 2013 Aug;12(8):756-67. Epub 2013 Jun 11. Erratum in: Lancet Neurol. 2013 Sep;12(9):846.

Link

https://doi.org/10.1016/s1474-4422(13)70102-9

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS

A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?

Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study

RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis